These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 8946864

  • 1. Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer.
    Goldberg JM, Piver MS, Hempling RE, Recio FO.
    Gynecol Oncol; 1996 Dec; 63(3):312-7. PubMed ID: 8946864
    [Abstract] [Full Text] [Related]

  • 2. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.
    Forum (Genova); 2000 Dec; 10(4):323-32. PubMed ID: 11535983
    [Abstract] [Full Text] [Related]

  • 3. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A, Kosmas C, Tsavaris N, Toufexi H, Lagadas A, Gogas H, Giannakopoulos K, Kouraklis G, Griniatsos J, Felekouras E, Tsigris C, Nikiteas N, Papadopoulos O, Giannopoulos A.
    Anticancer Res; 2007 Dec; 27(3B):1645-51. PubMed ID: 17595790
    [Abstract] [Full Text] [Related]

  • 4. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
    Zanetta G, Fei F, Mangioni C.
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
    [Abstract] [Full Text] [Related]

  • 5. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR, Aghajanian C, Barakat RR, Fennelly D, Shapiro F, Spriggs D.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [Abstract] [Full Text] [Related]

  • 6. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
    Hoekstra AV, Hurteau JA, Kirschner CV, Rodriguez GC.
    Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
    [Abstract] [Full Text] [Related]

  • 7. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
    Roland PY, Barnes MN, Niwas S, Robertson MW, Alvarez R, Austin JM, Kilgore LC, Partridge EE.
    Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
    [Abstract] [Full Text] [Related]

  • 8. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A, Mendiola C, del Campo JM, Massuti B, Casado A, Escobedo A, Moyano A, Ojeda B, Poveda A, Benito D.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [Abstract] [Full Text] [Related]

  • 9. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Covens A, Blessing J, Bender D, Mannel R, Morgan M, Gynecologic Oncology Group.
    Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
    [Abstract] [Full Text] [Related]

  • 10. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.
    Kurbacher CM, Bruckner HW, Cree IA, Kurbacher JA, Wilhelm L, Pöch G, Indefrei D, Mallmann P, Andreotti PE.
    Clin Cancer Res; 1997 Sep; 3(9):1527-33. PubMed ID: 9815839
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E, Guastalla JP, Weber B, Curé H, Orfeuvre H, Mousseau M, Vincent P, Diéras V, Tubiana-Mathieu N, Jacquin JP, Mignot L, Leduc B, Paraïso D, Viens P.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [Abstract] [Full Text] [Related]

  • 12. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, Skarlos D, Pavlidis N, Economopoulos T, Dimopoulos MA.
    Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
    [Abstract] [Full Text] [Related]

  • 13. Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM, Glisson BS, Khuri FR, Ginsberg L, Lawhorn K, Hong WK, Lippman SM.
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-33-S19-37. PubMed ID: 9427263
    [Abstract] [Full Text] [Related]

  • 14. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
    Morgan RJ, Braly P, Leong L, Shibata S, Margolin K, Somlo G, McNamara M, Longmate J, Schinke S, Raschko J, Nagasawa S, Kogut N, Najera L, Johnson D, Doroshow JH.
    Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
    [Abstract] [Full Text] [Related]

  • 15. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
    Worden FP, Moon J, Samlowski W, Clark JI, Dakhil SR, Williamson S, Urba SG, Ensley J, Hussain MH, Southwest Oncology Group, Head and Neck Working Group.
    Cancer; 2006 Jul 15; 107(2):319-27. PubMed ID: 16779801
    [Abstract] [Full Text] [Related]

  • 16. [Chemotherapy for recurrent ovarian cancer].
    Nishimura H, Imamura K, Chang C.
    Gan To Kagaku Ryoho; 1996 Aug 15; 23(9):1124-8. PubMed ID: 8751798
    [Abstract] [Full Text] [Related]

  • 17. A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer.
    Adachi S, Ogasawara T, Ito K, Koyama M, Nagano T, Suzuki A, Yamada T, Nakata Y, Ozawa M.
    Oncol Rep; 2001 Aug 15; 8(2):285-8. PubMed ID: 11182041
    [Abstract] [Full Text] [Related]

  • 18. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV, Aravantinos G, Kosmidis P, Athanassiadis A, Stathopoulos GP, Pavlidis N, Bafaloukos D, Karphathios S, Papakostas P, Bamia C, Fountzilas G.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [Abstract] [Full Text] [Related]

  • 19. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
    Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Lele SB, Marchetti DL, Baker TR, Blumenson LE.
    Gynecol Oncol; 1998 Sep 15; 70(3):392-7. PubMed ID: 9790793
    [Abstract] [Full Text] [Related]

  • 20. Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial.
    Braly PS, Berek JS, Blessing JA, Homesley HD, Averette H.
    Gynecol Oncol; 1995 Feb 15; 56(2):164-8. PubMed ID: 7896179
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.